On Jul. 21, 2020, Bio-Techne announced that Exosome Diagnostics, a Bio-Techne brand, had completed validation testing for COVID-19 caused by the novel coronavirus (SARS-CoV-2) and offers the ExoCovid-19 test for detection of the virus in patient samples. The ExoCovid-19 test will be performed in its CLIA-certified, CAP-accredited laboratory.

Exosome Diagnostics, the world leader in developing exosomal liquid biopsy-based diagnostic assays, has expanded its high-complexity laboratory capabilities to perform qualitative multiplexing nucleic acid analysis for the sensitive detection and identification of SARS-CoV-2 virus in nasal, nasopharyngeal, and bronchoalveolar lavage patient specimens. 

Exosome Diagnostics has validated the CDC-approved assay which has been granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration for detection of SARS-CoV-2. Unlike many of the earlier tests currently available on the market, the ExoCovid-19 collection kit offers a minimally invasive nasal swab (anterior nares) which enables patients to comfortably self-collect a specimen while maintaining physical distancing from a healthcare provider.